---
title: "Spatial CD8+ T Cell–Macrophage Niche Drives Checkpoint Inhibitor–Related Hepatotoxicity"
id: "medrxiv-4-macrophage-cd8-t-cell-spatial-coupling-defines-an-innate-adaptive-injury-niche"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-4-macrophage-cd8-t-cell-spatial-coupling-defines-an-innate-adaptive-injury-niche"
content_type: "clinical_feed_article"
specialty: "Gastroenterology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.18.26360744v1?rss=1"
published_at: "2026-08-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Spatial CD8+ T Cell–Macrophage Niche Drives Checkpoint Inhibitor–Related Hepatotoxicity
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-4-macrophage-cd8-t-cell-spatial-coupling-defines-an-innate-adaptive-injury-niche
- **Specialty:** [Gastroenterology](https://medichelpline.com/clinical-feed/gastroenterology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.18.26360744v1?rss=1)
- **Published At:** 2026-08-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Study used **imaging mass cytometry** with a 32-marker panel to profile human liver biopsies from checkpoint inhibitor hepatotoxicity (ILICI), autoimmune hepatitis (AIH), and healthy controls, generating spatially resolved single-cell proteomic data across 144 regions of interest and ~297,000 single cells. - Cohorts included ILICI (n = 12), AIH (n = 14), and healthy control liver (n = 2); apoptosis and pyroptosis were detected by cleaved caspase-3 (cC3) and cleaved gasdermin D (cGSDMD) respectively. - Histiocyte-rich granulomas were a distinguishing histologic feature in ILICI, composed principally of **macrophages** and **CD8+ T cells**, including activated memory-effector CD8+ subsets. - Permutation-based spatial analysis identified **CD8+ T cell–macrophage co-localization** as the most frequent significant interaction in ILICI, forming integrated innate–adaptive cellular neighborhoods that concentrated cC3- and cGSDMD-positive cells. - In contrast, AIH showed more spatial compartmentalization of immune cells and stroma rather than tightly coupled CD8–macrophage neighborhoods. - Densities of **CD8+ T cells** and macrophages correlated with Ishak necroinflammation scores, clinical jaundice, and granuloma formation in ILICI samples. - The human data recapitulate a previously described tri-cellular **CD8–macrophage–hepatocyte** injury niche from a murine model, suggesting conserved mechanisms between species. - Authors propose that myeloid signaling and CD8–macrophage interactions are candidate liver-directed targets to dissociate hepatotoxicity from antitumor immune activity, though the study is a preprint and not yet peer-reviewed. - Raw IMC images and processed single-cell objects are deposited in the BioImage Archive (S-BIAD3614); ethical approvals and informed consent were obtained and funders are listed in the source.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=U63ORCpscAHmW1wppZwK.5pdv51HMv8bqMUwtAftUDY-1787370722.8493395-1.2.1.1-j9odOrOYXknGvBUTJK0WbCc7LOEcnNYo4QhSpArDDBvHEbakkAthpc8bna_txkMg) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.18.26360744v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Macrophage-CD8+ T Cell Spatial Coupling Defines an Innate-Adaptive Injury Niche in Human Checkpoint Inhibitor Hepatotoxicity [ View ORCID Profile](http://orcid.org/0000-0002-1064-7487)Jacob M. Bogdanov, [ View ORCID Profile](http://orcid.org/0009-0007-6787-4959)Neil Zhao, Helia Alavifard, [ View ORCID Profile](http://orcid.org/0000-0003-3442-4453)David E. Kleiner, [ View ORCID Profile](http://orcid.org/0000-0001-9161-5892)Robert J. Fontana, [ View ORCID Profile](http://orcid.org/0000-0002-1443-9351)Andrew A. Stolz, [ View ORCID Profile](http://orcid.org/0000-0001-7472-822X)Akil Merchant, [ View ORCID Profile](http://orcid.org/0000-0002-9244-5888)Jonathan Z. Sexton, [ View ORCID Profile](http://orcid.org/0000-0002-0121-7186)Lily Dara doi: https://doi.org/10.64898/2026.08.18.26360744 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Jacob M. Bogdanov 1 Division of GI and Liver Diseases, Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA; Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospita; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jacob%2BM.%2BBogdanov%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bogdanov%20JM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJacob%2BM.%2BBogdanov%2B) * [ORCID record for Jacob M. Bogdanov](http://orcid.org/0000-0002-1064-7487 "Open in new tab") Neil Zhao 2 Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, MI, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Neil%2BZhao%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Zhao%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANeil%2BZhao%2B) * [ORCID record for Neil Zhao](http://orcid.org/0009-0007-6787-4959 "Open in new tab") Helia Alavifard 3 Division of GI and Liver Diseases, Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Helia%2BAlavifard%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Alavifard%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHelia%2BAlavifard%2B) David E. Kleiner 4 Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=David%2BE.%2BKleiner%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kleiner%20DE&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADavid%2BE.%2BKleiner%2B) * [ORCID record for David E. Kleiner](http://orcid.org/0000-0003-3442-4453 "Open in new tab") Robert J. Fontana 5 Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Robert%2BJ.%2BFontana%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Fontana%20RJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARobert%2BJ.%2BFontana%2B) * [ORCID record for Robert J. Fontana](http://orcid.org/0000-0001-9161-5892 "Open in new tab") Andrew A. Stolz 3 Division of GI and Liver Diseases, Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Andrew%2BA.%2BStolz%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Stolz%20AA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAndrew%2BA.%2BStolz%2B) * [ORCID record for Andrew A. Stolz](http://orcid.org/0000-0002-1443-9351 "Open in new tab") Akil Merchant 6 Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Akil%2BMerchant%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Merchant%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAkil%2BMerchant%2B) * [ORCID record for Akil Merchant](http://orcid.org/0000-0001-7472-822X "Open in new tab") Jonathan Z. Sexton 5 Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jonathan%2BZ.%2BSexton%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sexton%20JZ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJonathan%2BZ.%2BSexton%2B) * [ORCID record for Jonathan Z. Sexton](http://orcid.org/0000-0002-9244-5888 "Open in new tab") Lily Dara 3 Division of GI and Liver Diseases, Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lily%2BDara%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Dara%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALily%2BDara%2B) * [ORCID record for Lily Dara](http://orcid.org/0000-0002-0121-7186 "Open in new tab") * For correspondence: lily.dara@usc.edu * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.18.26360744v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1283344/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.18.26360744v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1283344/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.18.26360744v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1283344/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.08.18.26360744v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1283344/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.18.26360744v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1283344/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.18.26360744v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1283344/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background & Aims: Immune-mediated liver injury from immune checkpoint inhibitors (ILICI) is a major immune-related adverse event that limits cancer immunotherapy, yet its tissue-level immunobiology is poorly defined and its management is largely extrapolated from autoimmune hepatitis (AIH). We previously identified a tri-cellular CD8+ T cell-macrophage-hepatocyte injury niche in a murine model of ILICI; here, we tested whether this niche is recapitulated in human disease. Methods: We applied imaging mass cytometry with a 32-marker panel to liver biopsies from patients with ILICI (n = 12), AIH as a disease comparator (n = 14), and healthy controls (n = 2), profiling approximately 297,000 single cells across 144 regions of interest with spatially resolved detection of apoptosis (cleaved caspase-3, cC3) and pyroptosis (cleaved gasdermin D, cGSDMD). Results: We detected histiocyte-rich granulomas in ILICI consisting of macrophages and CD8+ T cells, including activated memory-effector subsets. Permutation-based spatial analysis identified CD8+ T cell-macrophage co-localization as the most frequent significant interaction in ILICI, organizing into integrated innate-adaptive cellular neighborhoods that concentrated cC3- and cGSDMD-positive cells. Descriptively, this contrasted with AIH, in which immune cells and stroma were more spatially compartmentalized. CD8+ T-cell and macrophage densities correlated with Ishak necroinflammation scores, jaundice, and granuloma formation. Conclusions: These findings provide the first single-cell spatial proteomic characterization of human ILICI in situ; they recapitulate the tri-cellular CD8-macrophage-hepatocyte niche we previously defined in a murine model and characterize ILICI as a spatially organized innate-adaptive inflammatory process, nominating myeloid signaling and CD8-macrophage interactions as candidate liver-directed targets to uncouple hepatotoxicity from anti-tumor immunity. ### Competing Interest Statement JBM, NZ, DK, and AM declare no conflicts of interest. [Remaining author disclosures are pending and will be provided prior to final submission.] ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics approval The Institutional Review Board of the University of Southern California gave ethical approval for this work. The Institutional Review Board of Advarra, serving as the central IRB for the Drug-Induced Liver Injury Network (DILIN), gave ethical approval for this work. Written informed consent was obtained from each patient included in the study. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability Raw IMC images, processed single-cell objects, and per-ROI metadata are available in BioImage Archive Submission - S-BIAD3614 (DOI: 10.6019/S-BIAD3614). ## Funder Information Declared National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, U01DK065211, U01DK065184, U01DK065201, U01DK083020, U01DK083027, U24DK065176, R01DK144042 National Institute of General Medical Sciences (NIGMS), National Institutes of Health, T32GM141746, R01GM152417 National Cancer Institute (NCI), National Institutes of Health (Intramural Program) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (Intramural Program) Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.18.26360744v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.19.26360772v1 "Opportunities for targeted HIV prevention programs: measuring prevention gaps at public health facilities and social venues in Malawi")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.18.26360725v1 "Temporal pole blurring in hippocampal sclerosis reflects seizure-disrupted myelination") Posted August 21, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.18.26360744v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/21/2026.08.18.26360744.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.18.26360744v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.08.18.26360744v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/21/2026.08.18.26360744.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Macrophage-CD8+ T Cell Spatial Coupling Defines an Innate-Adaptive Injury Niche in Human Checkpoint Inhibitor Hepatotoxicity Jacob M. Bogdanov, Neil Zhao, Helia Alavifard, David E. Kleiner, Robert J. Fontana, Andrew A. Stolz, Akil Merchant, Jonathan Z. Sexton, Lily Dara medRxiv 2026.08.18.26360744; doi: https://doi.org/10.64898/2026.08.18.26360744 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.18.26360744v1%26text%3DMacrophage-CD8%252B%2520T%2520Cell%2520Spatial%2520Coupling%2520Defines%2520an%2520Innate-Adaptive%2520Injury%2520Niche%2520in%2520Human%2520Checkpoint%2520Inhibitor%2520Hepatotoxicity "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.18.26360744v1%26t%3DMacrophage-CD8%252B%2520T%2520Cell%2520Spatial%2520Coupling%2520Defines%2520an%2520Innate-Adaptive%2520Injury%2520Niche%2520in%2520Human%2520Checkpoint%2520Inhibitor%2520Hepatotoxicity "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.18.26360744v1%26title%3DMacrophage-CD8%252B%2520T%2520Cell%2520Spatial%2520Coupling%2520Defines%2520an%2520Innate-Adaptive%2520Injury%2520Niche%2520in%2520Human%2520Checkpoint%2520Inhibitor%2520Hepatotoxicity%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.18.26360744v1%26title%3DMacrophage-CD8%252B%2520T%2520Cell%2520Spatial%2520Coupling%2520Defines%2520an%2520Innate-Adaptive%2520Injury%2520Niche%2520in%2520Human%2520Checkpoint%2520Inhibitor%2520Hepatotoxicity "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.18.26360744) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.18.26360744v1&count=horizontal&via=&text=Macrophage-CD8%2B%20T%20Cell%20Spatial%20Coupling%20Defines%20an%20Innate-Adaptive%20Injury%20Niche%20in%20Human%20Checkpoint%20Inhibitor%20Hepatotoxicity&counturl=www.medrxiv.org/content/10.64898/2026.08.18.26360744v1 "Tweet This") ## Subject Area * [Gastroenterology ](https://www.medrxiv.org/collection/gastroenterology) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (608) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (891) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (324) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4736) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (473) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (404) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (637) *
## Related Clinical Research

- [HBsAg clearance and occult HBV mutation in HIV/HBV-coinfected patients on ART](https://medichelpline.com/clinical-feed/medrxiv-7-hepatitis-b-surface-antigen-clearance-in-hiv-hbv-coinfected-patients-associated.md)
- [Social Determinants of Health Are More Common in HIV/HBV Coinfection Than in HIV or HBV Alone](https://medichelpline.com/clinical-feed/medrxiv-17-social-determinants-of-health-in-hiv-hbv-coinfection-compared-with-hiv-and-hbv.md)
- [Case report: ADMIO type 1 linked to de novo STAT3 gain-of-function mutation](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-a-case-report-of-admio-type-1-caused-by-a-de-novo-stat3-gain-of-function.md)
- [MMR vaccines: separating measles, mumps, rubella shots — myths and facts](https://medichelpline.com/clinical-feed/medical-news-today-0-should-the-measles-mumps-rubella-vaccines-be-separate-myths-vs-facts.md)
- [Stem-like CD8+ T cells preserve HBV-specific responses in HBV/HIV co-infection](https://medichelpline.com/clinical-feed/gut-14-stem-like-cd8-t-cells-preserve-hbv-specific-responses-in-hbv-hiv-co-infection.md)

## Navigation
- [← Back to Gastroenterology Feed](https://medichelpline.com/clinical-feed/gastroenterology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.